Navigation Links
Emerging lymphoma and myeloma treatments focus on improving individual patient response
Date:12/12/2011

p>

Dr. Meyer will present this study in an oral presentation on Monday, December 12, at 3:00 p.m. PST at the San Diego Convention Center in Ballroom 20A.

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study [Abstract 269]

The first clinical trial to directly compare rituximab with the new anti-CD20 monoclonal antibody obinutuzumab for the treatment of relapsed non-Hodgkin lymphoma (NHL) has shown higher response rates for patients treated with the novel therapy.

NHL survival rates have increased dramatically in the last several decades because of such proven and effective targeted therapies as rituximab that aim directly at the key molecular features of the disease. Despite advances in NHL treatment, hematologists continue to be challenged by drug resistance and disease relapses among their patients. Obinutuzumab, also known as GA101, is a new investigational therapy and the first type II bio-engineered monoclonal antibody specifically targeting CD20 (a prominent lymphoma biomarker) to be studied for use in NHL. Early research with GA101 has shown potential anti-lymphoma activity, but no studies have compared the results against current clinical options directly.

To compare the efficacy and safety of GA101 versus rituximab in patients with relapsed NHL, an international Phase II clinical trial was undertaken measuring overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety outcomes among patients on both treatments. A total of 175 patients were randomized to receive four weekly injections of either GA101 or rituximab with response to treatment assessed between 28 and 42 days after the last dose. Those patients who responded to treatment received ongoing doses of GA101
'/>"/>

Contact: Lindsey Love
llove@hematology.org
540-538-9326
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Emerging public health crisis linked to mortgage default and foreclosure
2. Emerging pharmaceutical platform may pose risks to retinal health
3. Georgia Tech researchers receive 3 NSF Emerging Frontiers awards
4. ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer
5. ATS issues report on emerging issues in HIV-associated pulmonary disease
6. Emerging drug class may enhance red blood cell production in anemic patients
7. New Society for Social Neuroscience to help guide emerging field
8. Live streaming of emerging brain science and health news
9. Emerging E. coli strain causes many antimicrobial-resistant infections in US
10. Neuxpower Selected as 2010 Emerging Technology Vendor by CRN Magazine
11. Experts explore emerging evidence linking diabetes and cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Bronx, NY (PRWEB) , ... September 01, 2015 , ... ... for 86 children and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place ... camp staff included 65 adult counselors, some of whom work for Calvary, and two ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer to have ... Surgery, according to a new survey that also offers insight on why that ... – which reflects views on cosmetic medical treatments and ratings for 10 specific ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in ... MonaLisa Touch® , an innovative vaginal health laser procedure that prevents and resolves ... treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its ... disciplines since its inception more than 35 years ago. A pilot program begun by ... teachers - and, not just those intent on pursuing careers in these fields. The ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nelson, D.O., has joined its medical management team as an Associate Medical Director. ... all sizes and types in the U.S. and abroad. , Dr. Nelson ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3
... (LTR) at the LSU Health Sciences Center New Orleans ... million contract over seven years by the National Cancer ... Epidemiology and End Results) Program-designated cancer registry. There are ... States., "The SEER Program is the most authoritative source ...
... if therapeutic anticancer vaccines, which are designed to boost ... developed. For example, the viruses used to deliver the ... targeted by the patient,s immune system, inducing neutralizing and ... by Michael Morse, at Duke University Medical Center, Durham, ...
... By Amanda Gardner HealthDay Reporter , MONDAY, Aug. ... to fashion a therapeutic vaccine that appears to attack a ... required tumor-fighting immune response in early human trials, but only ... urged caution. "They were able to generate an immune ...
... N.C., Aug. 2 - Merz Pharmaceuticals today announced that ... has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type ... or blepharospasm. According to an epidemiology study conducted in ... cervical dystonia and blepharospasm, is estimated at 295 per ...
... able to significantly reduce the radiation dose associated with ... one day dose optimization workshop provided by the Royal ... supported by the local state health department, according to ... Journal of the American College of Radiology (www.jacr.org). ...
... A study in the Aug. 1 issue of the journal ... age male infants are easier to arouse than females during quiet ... no significant gender differences in arousability. The results suggest that ... may not reflect a pre-existing vulnerability involving arousal responses. Results ...
Cached Medicine News:Health News:LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI 2Health News:LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI 3Health News:Vaccine Shows Some Promise Against Advanced Cancers 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 3Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 4Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 2Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 3
(Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: